C4X Discovery Ltd’s Post

The biotechnology sector, facing a prolonged downturn, received a potential boost with the Federal Reserve's signal to cut interest rates in 2024. Analysts predict a positive impact on biotech stocks, but clinical trial outcomes remain crucial. Ten imminent trials could influence the sector, including Vertex's VX-548 for acute pain, Alnylam's vutrisiran in transthyretin amyloidosis cardiomyopathy, Roche's tiragolumab in lung cancer, and Moderna's mRNA vaccines for influenza and COVID-19. Other key trials involve Amylyx's Relyvrio for ALS, Johnson & Johnson's aticaprant for major depressive disorder, Gilead's Trodelvy in lung cancer, Sanofi's tolebrutinib in multiple sclerosis, Pfizer's gene therapy for Duchenne muscular dystrophy, and Beam's base editing for sickle cell disease. See BiopharmaDive's article on '10 clinical trials to watch in the first half of 2024' https://lnkd.in/eQEUx3KX

China's NRDL 2023 marked a record for formulary expansion, including several new breakthroughs. Bruce Liu and colleagues discuss the developments in their new article. Learn more about the evolving value rating system as well as the impact on oncology and rare diseases here: https://lnkd.in/eh92SAvF #Healthcare #Pharma #Biotech #MarketStrategy #SimonKucher

We are excited to announce Deciduous Therapeutics as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Deciduous Therapeutics is a San Francisco based, venture backed start-up focused on harnessing the immune system to treat diseases of aging. Specifically, the company is focused on restoring natural killer t-cell function to systemically ablate pathological senescent cells. The company had demonstrated that a single dose of its proprietary NKT agonist is able to selectively remove senescent cells, resulting in disease resolution in both fibrosis and metabolic disease models. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/ggNnNTeh #ARDD2024 #DrugDiscovery #AgingResearch

𝗔 𝐔𝐥𝐭𝐢𝐦𝐚𝐭𝐞 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 𝐋𝐢𝐯𝐞𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 @  https://lnkd.in/gDee2gVv The Liver Cancer Therapeutics Market was valued at USD 3,625.43 million in 2023 and is projected to reach USD 15,903.20 million by 2031, growing at a compound annual growth rate (CAGR) of 20.3% from 2024 to 2031. The Liver Cancer Therapeutics Market is witnessing rapid growth, propelled by rising incidences of liver cancer globally and advancements in therapeutic options. Innovations in targeted therapies, immunotherapies, and combination treatments are significantly enhancing patient outcomes, driving market expansion. Increased awareness and early diagnosis, coupled with substantial investments in research and development, are also contributing to this growth. Moreover, regulatory approvals for new drugs and treatments are accelerating the availability of advanced therapies. As healthcare providers strive to improve survival rates and quality of life for liver cancer patients, the demand for effective and innovative therapeutic solutions continues to rise, positioning the market for robust growth in the coming years. 𝐓𝐡𝐞 𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬  Imclone Systems Incorporated .,  Alnylam Pharmaceuticals .,  F. Hoffmann-La Roche Ltd., Onyx Pharmaceuticals, Inc., an Amgen subsidiary ., ArQule U.K. Ltd a Co ,  Pfizer ., Celsion Corporation Corp., Jennere Biotherapeutics Inc., 4SC AG,  Bayer Schering Pharma,  and other players. #ImCloneSystems #AlnylamPharmaceuticals #Roche #OnyxPharmaceuticals #ArQule #Pfizer #Celsion #JennereBiotherapeutics #4SC #BayerScheringPharma #Biotech #Pharma #CancerResearch #DrugDevelopment #Pharmaceuticals #Biopharma #HealthcareInnovation #MedicalResearch #LiverCancerTherapeutics #ClinicalTrials #LiverCancer #CancerTherapeutics #LiverCancerTreatment #Oncology #CancerResearch #Immunotherapy #TargetedTherapy #MedicalInnovation #PharmaIndustry #Biotech #Healthcare #CancerCare #ClinicalTrials #DrugDevelopment #PrecisionMedicine #CancerSurvivorship #HealthTech #Pharmaceuticals #Hepatology #CancerAwareness

Gene&Cell Therapy >> Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from Sanofi: Jean-Paul Clozel → Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Clozel will retire as CEO on June 13, and Idorsia has tapped his longtime lieutenant André Muller to replace him. The 69-year-old Clozel will now stand for election as chairman, while Mathieu Simon moves into the vice chairman post. The changes on the board don’t stop there. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping down, and Idorsia has nominated ex-Galapagos president Bart Filius. “It has been an absolute privilege to serve as CEO of Actelion and Idorsia for the past 24 years. I can think of no greater endeavor than discovering new medicines that help patients lead better lives,” Clozel said in a statement. “Having devoted so much energy to Idorsia, I want to stay engaged and support the company to realize its potential.” Muller was CFO at Actelion and followed Clozel to Idorsia as finance chief after J&J bought Actelion for $30 billion in 2017. Muller had a 17-year career at Pierre Fabre, where he was CFO from 2002-11. Idorsia has notched two FDA approvals in its seven-year history: insomnia med Quviviq and high blood pressure drug Tryvio. Naimish Patel → CRISPR Therapeutics has found a new medical chief and promoted one of its execs. Naimish Patel takes over as CMO from PK Morrow, who resigned on Jan. 26 and joined Takeda as head of the oncology therapeutic area unit. Patel quickly moved up to global program head for the megablockbuster Dupixent early in his tenure at Sanofi, where he was recently the head of global development in immunology and inflammation. Vertex’s Casgevy partner has also elevated Julianne Bruno to COO. She left McKinsey for CRISPR in 2019 and had been SVP and head of programs & portfolio management since March 2023. → Bavarian Nordic will be looking for a CMO after Laurence de Moerlooze’s departure at the end of the month. The GSK and Takeda vaccines alum succeeded Chris Heery as medical chief in the spring of 2020. “We have an operational setup that is robust enough for people to continue doing their jobs until a replacement is in place,” Bavarian Nordic CEO Paul Chaplin told MedWatch about the search. “They can manage that for six months or more, so I have no concerns at all.” Hanneke Schuitemaker → Meanwhile, at another vaccine developer, Valneva has welcomed Hanneke Schuitemaker as CSO. As J&J’s global head of viral vaccine discovery and translational medicine, Schuitemaker was involved in the development of vaccine candidates for Covid-19, HIV, RSV, Ebola and more. Valneva overcame a nearly two-and-a-half-month delay and received an accelerated nod from the FDA last November for its… #lucidquest #genetherapy #celltherapy

Swiss #pharmaceuticalgiant Roche Holding AG has inked a deal with Sangamo Therapeutics, Inc. as the company continues its pursuit of an effective treatment for #Alzheimersdisease. The deal was announced on Tuesday through Roche’s Genentech research arm.  Roche has licensed Sangamo’s zinc finger technology to develop #genomicmedicines for specific #neurodegenerativediseases. This agreement grants Roche exclusive rights to molecules designed to suppress the #gene responsible for producing #tau, a protein considered a key factor in #Alzheimer’s disease.  Additionally, Roche has secured rights to molecules targeting a second, undisclosed neurology target and a newly discovered adeno-associated virus capsid. This microscopic shuttle has demonstrated the ability to cross the #bloodbrainbarrier in primate studies, potentially addressing significant challenges in #braindrugdevelopment. According to Sangamo CEO Sandy Macrae this... More at #Proactive #ProactiveInvestors #biotech http://ow.ly/a30w105EBgI

Targeting SARS-CoV-2: A Comprehensive Mechanistic Approach The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, has posed an unprecedented global health challenge. Developing effective therapeutic interventions and diagnostic tools has become a top priority for researchers, pharmaceutical companies, and biotechnology firms worldwide. Despite the immense efforts and resources dedicated to this endeavor, directly targeting the virus and its intricate mechanisms has proven to be a formidable task. However, recent advancements in our understanding of SARS-CoV-2 and its interactions with the host have paved the way for innovative strategies to combat this virus through various mechanisms of action (MoAs). OniX AI's comprehensive report on SARS-CoV-2 therapeutic candidates and diagnostic platforms provides an in-depth analysis of these diverse approaches, offering a powerful tool for researchers, drug developers, and industry professionals in their quest to mitigate the impact of this pandemic. https://lnkd.in/d_bPbcD

Here are the #Top #10 #Drug #makers in #2024 1. #Novartis led by Vas Narasimhan, focusing on technology integration. (Projected 2024 sales: $53.2 billion) 2. #Pfizer's growth driven by Ibrance, Prevnar, and biosimilars. (Projected 2024 sales: $51.2 billion) 3. #Roche's success with Ocrevus and Hemlibra. (Projected 2024 sales: $50.6 billion) 4. #J&J's strong growth with Imbruvica, Tremfya, and Stelara. (Projected 2017 sales: $47.7 billion.) 5. #Sanofi's strategic roadmap includes Dupixent and Kevzara. (Projected 2024 sales: $47.4 billion ) 6. #GSK's focus on HIV, respiratory, vaccines, and oncology. (Projected 2024 sales: $38.4 billion ) 7. #Merck's reliance on Keytruda and vaccine segment. (Projected 2024 sales: $38.0 billion) 8. #AbbVie sustained by Humira, eyeing successors like Imbruvica. (Projected 2024 sales: $37.2 billion) 9. #AstraZeneca's turnaround strategy shows promise. (Projected 2024 sales: $31.7 billion) 10. #Bristol-Myers Squibb focus on immuno-oncology drug Opdivo and cardiovascular blockbuster Eliquis (Projected 2024 sales: $28.7 billion) #Market #Overview: Top 10 #drugmakers of #2024 to hold 35% of the total biopharma market share. Projected sales for these companies exceed $420 billion. #Sales #Predictions: Novartis projected to have $53.2 billion in sales in 2024. Pfizer follows with $51.2 billion, Roche at $50.6 billion, J&J at $47.7 billion, and Sanofi at $47.4 billion. #PharmaSales #2024Projections #Noteworthy #points : #Novartis relies on a range of offerings, including #Cosentyx and #Entresto. #Pfizer's growth driven by #Ibrance and #Prevnar. #Roche's success attributed to #Ocrevus, #Perjeta, and #Hemlibra. #PPInsights #PharmaIndustry #BiopharmaLeaders #MarketShare2024 #SalesProjections #TopPharmaCompanies #HealthcareReport #EYParthenonInsights #PharmaConsulting #DrugSales #MedicalTrends #CancerMedications #ImmunologySales #PharmaGrowth #TherapeuticFocus #FutureOutlook #CompanyHighlights #IndustryChallenges #Healthcare2024 #BiopharmaSuccess #EYAdvisory #PharmaForecast #StrategicRoadmap #PricingScrutiny #MarketCompetition #HealthcareStrategy

Everything you missed in #Pharma & #Biotech 🦠🔬   ✅ Approvals FDA approves Iovance Biotherapeutics, Inc.'s Amtagvi as first T-cell therapy for a solid tumor (advanced melanoma) Vertex Pharmaceuticals and CRISPR Therapeutics secure positive CHMP opinion for Casgevy, the only gene therapy in Europe for sickle cell disease and transfusion-dependent beta-thalassemia (TDT)   Ipsen’s Onivyde approved by FDA in first-line metastatic pancreatic adenocarcinoma (mPDAC) Biogen receives European Commission approval for SKYCLARYS® (omaveloxolone), first therapy for Friedreich’s Ataxia   Eli Lilly and Company's weight-loss drug Mounjaro launched in the UK   💸 Deals   Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion, expanding liver portfolio with late-stage asset Seladelpar    Alys Pharmaceuticals launches with $100 million, focusing on developing treatments for skin diseases, by merging 6 Medicxi companies.   BioAge Labs secures $170 Series D financing to accelerate development of obesity and metabolic disease therapeutics   🎯Late-stage developments   Johnson & Johnson's nipocalimab meets primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease   📈 Access   PhRMA lawsuit challenging Medicare drug price negotiations dismissed by federal judge.  Negotiation of “fair prices” for drugs are a key IRA feature impacting access and pricing. CMS issues second part of draft guidance to allow Medicare patients to pay out-of-pocket prescription drug costs in monthly payments 👉 What’s your favorite industry news? #pharma #biotech #PULSENews

Didn’t get a chance to talk to us at #ASH2023? Read the first part of our latest blog series “Old biomarkers, new tricks” which discusses our insights from the December meeting! Leila Luheshi, VP Pharma Partnering, describes the potential of menin inhibitors for acute leukaemia, including the use of IVDR approved FISH probes in clinical trials. Read Part 1 of this series here: https://lnkd.in/gkFpYFAc